ARTICLE | Clinical News
BG-777: Virocell will begin an open-label, dose-escalation Canadian Phase I trial in 20 healthy volunteers.
April 8, 2002 7:00 AM UTC
Virocell Inc., St. Foy, Quebec Product: BG-777 Business: Infectious diseases Therapeutic category: Immune modulation Target: NA Description: NA Indication: Treat HIV/AIDS Endpoint: Safety and pharmaco...